JNJ-26990990 是一种广谱抗惊厥药，是上市药物托吡酯的第二代后续药物。它被设计成具有与托吡酯相同的抗惊厥作用，但没有与托吡酯的碳酸酐酶抑制相关的副作用。它还具有治疗炎症性疼痛、神经性疼痛和抑郁症的潜在用途。

JNJ-26990990 is a broad-spectrum anticonvulsant drug as a second-generation followup to the marketed drug topiramate. It was designed to have the same anticonvulsant effects as topiramate, but without the side effects associated with topiramate's carbonic anhydrase inhibition. It also has potential use in the treatment of inflammatory pain, neuropathic pain, and depression. JNJ-26990990 entered phase II clinical trials in October 2007.

877316-38-6

C9H10N2O2S2

242.32

JNJ-26990990

DMSO:65 mg/ml (268.24 mM)
Powder: -20°C for 3 years
In solvent: -80°C for 2 years